Amgen (AMGN.US) Q3 revenue and profit beat expectations, and it raised its full-year guidance.

Amgen (AMGN.US) released its Q3 2026 report after the U.S. market close on November 3: total revenue was $10.365 billion, up 8% year-over-year, above the market estimate of about $10.05 billion; non-GAAP EPS was $6.45, up 14% year-over-year, significantly above the estimate of $5.77; GAAP EPS was $7.08, up 19% year-over-year. Growth products continued to gain traction: UPLIZNA revenue was $451 million, up 191% year-over-year; IMDELLTRA revenue was $406 million, up 128%; TEZSPIRE revenue was $538 million, up 43%; EVENITY revenue was $751 million, up 39%; Repatha revenue was $1.085 billion, up 37%. Older products were clearly hit by biosimilars: Prolia revenue was $632 million, down 45% year-over-year; XGEVA revenue was $288 million, down 47%; Otezla revenue was $481 million, down 18%. A total of 17 products achieved double-digit sales growth in the quarter. The company also raised its full-year 2026 guidance: total revenue was raised to $38.9 billion to $39.7 billion from the previous expectation of $38.2 billion to $39.4 billion; non-GAAP EPS was raised to $22.90 to $23.70 from $22.30 to $23.50. Although both the results and guidance beat expectations, Amgen's stock fell after hours. As of press time, the stock was down 1.6% after hours.